Isomerase scaling at Chesterford Research Park
Isomerase has secured the first pre-let within the Newnham Building at Chesterford Research Park.
The move to Suite 4 of the new building on its completion in mid-2020 will facilitate planned future growth for the successful natural products discovery and development provider.
The Newnham Building is currently being re-configured to create a detached two storey lab/R & D building in a prominent position on the park. The flexibility of the building has enabled it to be divided into four individual suites, which can cater for a range of needs in terms of technical configuration.
Interest in the Newnham Building is high, with two further suites under offer, leaving just one remaining suite of 11,518 sq ft available.
Isomerase joined the Chesterford Research Park community in 2013, initially taking a single laboratory within the multi-let Science Village building. Since then it has seen sustained growth and the company has expanded its occupancy with an additional suite to accommodate an enlarged team of 30 people.
During its occupancy at the Science Village, Isomerase has established itself as one of the UK’s leading service providers to the global healthcare and biotechnology sectors, with particular expertise in the discovery and development of microbial natural products.
Dr Matt Gregory, co-founder and CEO said: “We have now reached the point in our development where we feel that a re-location to a larger, custom-fitted facility will really benefit and help facilitate our future growth.
“This move will enable us to further expand our capabilities, bring in new equipment and additional, highly skilled staff; guaranteeing our stability for the next decade.
“The Newnham Building is the ideal scenario for us; we really enjoy the environment here at Chesterford and working together with the park development team we have come up with an exciting fit-out design that meets both our current and future needs.”
In addition to Isomerase, the park is home to life science innovators including Arecor, AstraZeneca, Charles River Laboratories, Evonetix and Domainex. To date, more than 350,000 sq ft of laboratory R & D space has been let and occupied. Further phases of construction are proposed to extend the development to approximately one million sq ft.